Literature DB >> 17702789

Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.

M P J Garssen1, R van Koningsveld, P A van Doorn, I S J Merkies, M Scheltens-de Boer, J A van Leusden, I N van Schaik, W H J P Linssen, F Visscher, A M Boon, C G Faber, J Meulstee, M J J Prick, L H van den Berg, H Franssen, J A P Hiel, P Y K van den Bergh, C J M Sindic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17702789      PMCID： PMC2117875          DOI： 10.1136/jnnp.2006.102731

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  7 in total

Review 1.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

Review 2.  The immunobiology of Guillain-Barré syndromes.

Authors:  Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2005-06       Impact factor: 3.494

Review 3.  Mycophenolate mofetil and neurological diseases.

Authors:  P Vermersch; T Stojkovic; J de Seze
Journal:  Lupus       Date:  2005       Impact factor: 2.911

4.  Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.

Authors:  V Chaudhry; D R Cornblath; J W Griffin; R O'Brien; D B Drachman
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

Review 5.  Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.

Authors:  Kenneth C Gorson; Anthony A Amato; Allan H Ropper
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

Review 6.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  R A C Hughes; J C Raphaël; A V Swan; P A Doorn
Journal:  Cochrane Database Syst Rev       Date:  2004

7.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Authors:  R van Koningsveld; P I M Schmitz; F G Avander Meché; L H Visser; J Meulstee; P A van Doorn
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321
  7 in total
  18 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

3.  Peripheral neuropathies: current evidence for alternative treatment regimens and treatment combinations.

Authors:  C Sommer
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

Review 5.  New strategies in the management of Guillain-Barré syndrome.

Authors:  Jinting Xiao; Alain R Simard; Fu-Dong Shi; Junwei Hao
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 6.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

7.  Early recognition of poor prognosis in Guillain-Barre syndrome.

Authors:  C Walgaard; H F Lingsma; L Ruts; P A van Doorn; E W Steyerberg; B C Jacobs
Journal:  Neurology       Date:  2011-03-15       Impact factor: 9.910

8.  Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.

Authors:  Alex Y Doets; Hester F Lingsma; Christa Walgaard; Badrul Islam; Nowshin Papri; Amy Davidson; Yuko Yamagishi; Susumu Kusunoki; Mazen M Dimachkie; Waqar Waheed; Noah Kolb; Zhahirul Islam; Quazi Deen Mohammad; Thomas Harbo; Soren H Sindrup; Govindsinh Chavada; Hugh J Willison; Carlos Casasnovas; Kathleen Bateman; James A L Miller; Bianca van den Berg; Christine Verboon; Joyce Roodbol; Sonja E Leonhard; Luana Benedetti; Satoshi Kuwabara; Peter Van den Bergh; Soledad Monges; Girolama A Marfia; Nortina Shahrizaila; Giuliana Galassi; Yann Péréon; Jan Bürmann; Krista Kuitwaard; Ruud P Kleyweg; Cintia Marchesoni; María J Sedano Tous; Luis Querol; Isabel Illa; Yuzhong Wang; Eduardo Nobile-Orazio; Simon Rinaldi; Angelo Schenone; Julio Pardo; Frederique H Vermeij; Helmar C Lehmann; Volkan Granit; Guido Cavaletti; Gerardo Gutiérrez-Gutiérrez; Fabio A Barroso; Leo H Visser; Hans D Katzberg; Efthimios Dardiotis; Shahram Attarian; Anneke J van der Kooi; Filip Eftimov; Paul W Wirtz; Johnny P A Samijn; H Jacobus Gilhuis; Robert D M Hadden; James K L Holt; Kazim A Sheikh; Summer Karafiath; Michal Vytopil; Giovanni Antonini; Thomas E Feasby; Catharina G Faber; Cees J Gijsbers; Mark Busby; Rhys C Roberts; Nicholas J Silvestri; Raffaella Fazio; Gert W van Dijk; Marcel P J Garssen; Chiara S M Straathof; Kenneth C Gorson; Bart C Jacobs
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

9.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Alex Y Doets; Richard Ac Hughes; Ruth Brassington; Robert Dm Hadden; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2020-01-25

Review 10.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.